Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | RORC | P51449 | 7/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.33 |
| ▸ | RORA | P35398 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | RORB | Q92753 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17583151 | 0.87 | KMT2A (0.46) | CA2CA1HSD11B1KMT2AALDH1A1 | |
| SCHEMBL507274 | 0.85 | CA2 (0.42) | CA2CA1HSD11B1KMT2AALDH1A1 | |
| SCHEMBL17583126 | 0.84 | CA2 (0.38) | CA2CA1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL17583128 | 0.84 | CA2 (0.44) | CA2CA1KMT2ARORCPTPN11 | |
| SCHEMBL17583205 | 0.81 | CA2 (0.36) | CA2CA1HSD11B1KMT2A | |
| SCHEMBL2346377 | 0.76 | CA2 (0.37) | CA2CA1KMT2ARORCNR1I2 | |
| SCHEMBL17583193 | 0.76 | CA2 (0.41) | CA2CA1 | |
| SCHEMBL17315781 | 0.74 | CA2 (0.40) | CA2CA1KMT2ALMNAALDH1A1 | |
| SCHEMBL17589157 | 0.74 | POLB (0.35) | CA2CA1LMNAALDH1A1 | |
| SCHEMBL778365 | 0.74 | CA2 (0.67) | CA2CA1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106715435-B | Pyrrolopyrimidine derivatives as NR2B nmda receptor antagonist | 卢郡控股(开曼)有限公司 | 2019-10-01 | — | — | CN | disclosed |
| US-10420768-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2019-09-24 | — | — | US | disclosed |
| US-10420768-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2019-09-24 | — | — | US | disclosed |
| EP-3194403-B1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS CAYMAN LTD (KY) | 2019-02-06 | — | — | EP | disclosed |
| EP-3194403-B1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS CAYMAN LTD (KY) | 2019-02-06 | — | — | EP | disclosed |
| US-20180303834-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2018-10-25 | — | — | US | disclosed |
| US-9968610-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (US) | 2018-05-15 | — | — | US | disclosed |
| US-9968610-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (US) | 2018-05-15 | — | — | US | disclosed |
| US-9968610-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170209449-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-07-27 | — | — | US | disclosed |
| US-20170209449-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-07-27 | — | — | US | disclosed |
| US-20170209449-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-07-27 | — | — | US | disclosed |
| CN-106715435-A | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | 卢郡控股(开曼)有限公司 | 2017-05-24 | — | — | CN | disclosed |
| US-9567341-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-02-14 | — | — | US | disclosed |
| US-9567341-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-02-14 | — | — | US | disclosed |
| US-9567341-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-02-14 | — | — | US | disclosed |
| WO-2016044323-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2016-03-24 | — | — | WO | disclosed |
| US-20160075713-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2016-03-17 | — | — | US | disclosed |
| US-20160075713-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170209449-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN1, GRIN2A, GRIN2B | CA2 3557/4885CA1 2057/4885HSD11B1 2875/4885 |
| US-10420768-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | GRIN1, GRIN2A, GRIN2B | CA2 3557/4885CA1 2057/4885HSD11B1 2875/4885 |
| US-20160075713-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN1, GRIN2A, GRIN2B | CA2 3557/4885CA1 2057/4885HSD11B1 2875/4885 |
| US-20180303834-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN1, GRIN2A, GRIN2B | CA2 3557/4885CA1 2057/4885HSD11B1 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.